Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Mdm2: The Ups and Downs

Open access
Juven-Gershon, Tamar, Oren, Moshe·1999·Molecular Medicine

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/bf03402141

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 84

  1. Piette J, Neel H, Marechal V. (1997) Mdm2: keeping p53 under control. Oncogene 15: 1001–1010. · DOI · Paper page
  2. Momand J, Zambetti GP. (1997) Mdm-2: “big brother” of p53. J. Cell. Biochem. 64: 343–352. · DOI · Paper page
  3. Lozano G, Montes De Oca Luna R. (1998) MDM2 function. Biochim. Biophys. Acta 1377: M55–59.
  4. Cahilly-Snyder L, Yang FT, Francke U, George DL. (1987) Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 13: 235–244. · DOI · Paper page
  5. Fakharzadeh SS, Trusko SP, George DL. (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10: 1565–1569. · DOI · Paper page
  6. Momand J, Jung D, Wilczynski S, Niland J. (1998) The MDM2 gene amplification database. Nucl Acids Res. 26: 3453–3459. · DOI · Paper page
  7. Cordon-Cardo C, Latres E, Drobnjak M, et al. (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54: 794–799.
  8. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. (1993) MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 53: 16–18.
  9. Shibagaki I, Tanaka H, Shimada Y, et al. (1995) p53 mutation, Murine Double Minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin. Cancer Res. 1: 769–773.
  10. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53: 2736–2739.
  11. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP. (1994) Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res. 54: 4299–4303.
  12. Corvi R, Savelyeva L, Breit S, et al. (1995) Nonsyntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 10: 1081–1086.
  13. Landers JE, Haines DS, Strauss JR, George DL. (1994) Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9: 2745–2750.
  14. Landers JE, Cassel SL, George DL. (1997) Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 57: 3562–3568.
  15. Wurl P, Meye A, Schmidt H, et al. (1998) High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 16: 1183–1185. · DOI
  16. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ. (1993) Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8: 2353–2360.
  17. Haines DS, Landers JE, Engle LJ, George DL. (1994) Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell. Biol. 14: 1171–1178. · DOI
  18. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med. 2: 912–917. · DOI · Paper page
  19. Marechal V, Elenbaas B, Taneyhill L, et al. (1997) Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis. Oncogene 14: 1427–1433. · DOI
  20. Elenbaas B, Dobbelstein M, Roth J, Shenk T, Levine AJ. (1996) The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2: 439–451. · DOI · Paper page
  21. Marechal V, Elenbaas B, Piette J, Nicolas JC, Levine AJ. (1994) The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell. Biol. 14: 7414–7420. · DOI · Paper page
  22. Boddy MN, Freemont PS, Borden KL. (1994) The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends Biochem. Sci. 19: 198–199. · DOI
  23. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. (1998) Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17: 554–564. · DOI · Paper page
  24. Erhardt P, Tomaselli KJ, Cooper GM. (1997) Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J. Biol. Chem. 272: 15049–15052. · DOI
  25. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857–860. · DOI · Paper page
  26. Chen J, Lin J, Levine AJ. (1995) Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1: 142–152. · DOI · Paper page
  27. Barak Y, Juven T, Haffner R, Oren M. (1993) mdm2 expression is induced by wild-type p53 activity. EMBO J. 12: 461–468. · DOI · Paper page
  28. Juven T, Barak Y, Zauberman A, George DL, Oren M. (1993) Wild-type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411–3416.
  29. Wu X, Bayle JH, Olson D, Levine AJ. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7: 1126–1132. · DOI · Paper page
  30. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. (1995) A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucl. Acids Res. 23: 2584–2592. · DOI · Paper page
  31. Picksley SM, Lane DP. (1993) The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15: 689–690. · DOI · Paper page
  32. Chen J, Marechal V, Levine AJ. (1993) Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13: 4107–4114. · DOI · Paper page
  33. Lin J, Chen J, Elenbaas B, Levine AJ. (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8: 1235–1246. · DOI · Paper page
  34. Picksley SM, Vojtesek B, Sparks A, Lane DP. (1994) Immunochemical analysis of the interaction of p53 with MDM2—fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9: 2523–2529.
  35. Leng P, Brown DR, Deb S, Deb SP. (1995) Human oncoprotein MDM2 interacts with the TATA-binding protein in vitro and in vivo. Int. J. Oncology 6: 251–259.
  36. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ. (1993) The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 90: 11623–11627. · DOI · Paper page
  37. Wu L, Levine AJ. (1997) Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med. 3: 441–451. · DOI · Paper page
  38. Saucedo LJ, Carstens BP, Seavey SE, Albee LD, Perry ME. (1998) Regulation of transcriptional activation of mdm2 gene by p53 in response to UV radiation. Cell Growth Differ. 9: 119–130.
  39. Chen CY, Oliner JD, Zhan Q, Fornace AJ, Vogelstein B, Kastan MB. (1994) Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. U.S.A. 91: 2684–2688. · DOI · Paper page
  40. Price BD, Park SJ. (1994) DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res. 54: 896–899.
  41. Chang YC, Lee YS, Tejima T, et al. (1998) mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9: 79–84.
  42. Marston NJ, Jenkins JR, Vousden KH. (1995) Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10: 1709–1715.
  43. Kubbutat M, Ludwig RL, Ashcroft M, Vousden KH. (1998) Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol. 18: 5690–5698. · DOI · Paper page
  44. Prives C. (1998) Signaling to p53: breaking the MDM2-p53 circuit. Cell 95: 5–8. · DOI · Paper page
  45. Freedman DA, Levine AJ. (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18: 7288–7293. · DOI · Paper page
  46. Chen J, Wu X, Lin J, Levine AJ. (1996) mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16: 2445–2452. · DOI · Paper page
  47. Haupt Y, Barak Y, Oren M. (1996) Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15: 1596–1606. · DOI · Paper page
  48. Momand J, Zambetti GP. (1996) Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 12: 2279–2289.
  49. Banin S, Moyal L, Shieh S, et al. (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674–1677. · DOI · Paper page
  50. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PW. (1998) DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394: 700–704. · DOI · Paper page
  51. Barak Y, Oren M. (1992) Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J. 11: 2115–2121. · DOI
  52. Guerra B, Gotz C, Wagner P, Montenarh M, Issinger OG. (1997) The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation. Oncogene 14: 2683–2688. · DOI
  53. Mayo LD, Turchi JJ, Berberich SJ. (1997) Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57: 5013–5016.
  54. Henning W, Rohaly G, Kolzau T, Knippschild U, Maacke H, Deppert W. (1997) MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection. J. Virol. 71: 7609–7618. · DOI
  55. Bottger V, Bottger A, Howard SF, et al. (1996) Identification of novel mdm2 binding peptides by phage display. Oncogene 13: 2141–2147.
  56. Bottger A, Bottger V, Garcia EC, et al. (1997) Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269: 744–756. · DOI · Paper page
  57. Chen L, Agrawal S, Zhou W, Zhang R, Chen J. (1998) Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. U.S.A. 95: 195–200. · DOI · Paper page
  58. Midgley CA, Lane DP. (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179–1189. · DOI · Paper page
  59. Blaydes JP, Wynford-Thomas D. (1998) The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene 16: 3317–3322. · DOI
  60. Dahl AM, Beverley PC, Stauss HJ. (1996) A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol 157: 239–246. · doi:10.4049/jimmunol.157.1.239
  61. Xiao ZX, Chen J, Levine AJ, et al. (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694–698. · DOI · Paper page
  62. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue N, Kouzarides T. (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691–694. · DOI · Paper page
  63. Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X. (1997) E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 11: 1840–1852. · DOI · Paper page
  64. Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR. (1998) E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ. 9: 113–118.
  65. O’Connor DJ, Lam EW, Griffin S, et al. (1995) Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DPI. EMBO J. 14: 6184–6192. · DOI
  66. Sorensen TS, Girling R, Lee CW, Gannon J, Bandara LR, La Thangue N. (1996) Functional interaction between DP-1 and p53. Mol. Cell. Biol. 16: 5888–5895. · DOI
  67. Juven-Gershon T, Shifman O, Unger T, Elkeles A, Haupt Y, Oren M. (1998) The Mdm2 oncoprotein interacts with the cell fate regulator numb. Mol. Cell. Biol. 18: 3974–3982. · DOI
  68. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000. · DOI · Paper page
  69. Stott FJ, Bates S, James MC, et al. (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17: 5001–5014. · DOI · Paper page
  70. Bates S, Phillips AC, Clark PA, et al. (1998) p14ARF links the tumour suppressors RB and p53. Nature 395: 124–125. · DOI · Paper page
  71. de-Stanchina E, McCurrach ME, Zindy F, et al. (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12: 2434–2442. · DOI · Paper page
  72. Palmero I, Pantoja C, Serrano M. (1998) p19ARF links the tumour suppressor p53 to Ras. Nature 395: 125–126. · DOI · Paper page
  73. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. (1997) Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823–827. · DOI · Paper page
  74. Gu W, Shi XL, Roeder RG. (1997) Synergistic activation of transcription by CBP and p53. Nature 387: 819–823. · DOI · Paper page
  75. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175–1184. · DOI · Paper page
  76. Scolnick DM, Chehab NH, Stavridi ES, et al. (1997) CREB-binding protein and p300/CBP-as-sociated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 57: 3693–3696.
  77. Thomas A, White E. (1998) Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function. Genes Dev. 12: 1975–1985. · DOI
  78. McMasters KM, Montes De Oca Luna R, Pena JR, Lozano G. (1996) mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene 13: 1731–1736.
  79. Jones SN, Sands AT, Hancock AR, et al. (1996) The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc. Natl Acad. Sci. U.S.A. 93: 14106–14111. · DOI
  80. Dubs-Poterszman M, Tocque B, Wasylyk B. (1995) MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 11: 2445–2449.
  81. Sun P, Dong P, Dai K, Hannon GJ, Beach D. (1998) p53-independent role of MDM2 in TGFβ1 resistance. Science 282: 2270–2272. · DOI · Paper page
  82. Leveillard T, Gorry P, Niederreither K, Wasylyk B. (1998) MDM2 expression during mouse embryogenesis and the requirement of p53. Mech. Dev. 74: 189–193. · DOI
  83. Fiddler TA, Smith L, Tapscott SJ, Thayer MJ. (1996) Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol. Cell. Biol. 16: 5048–5057. · DOI
  84. Shvarts A, Bazuine M, Dekker P, et al. (1997) Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics 43: 34–42. · DOI

Cited by

Metadata

Authors
Juven-Gershon, T., & Oren, M.
Venue
Molecular Medicine
Published
1999-02
Volume
5
Issue
2
Pages
71-83
ISSN
  • 1076-1551 (ISSN-L)
  • 1528-3658
OpenAlex
W4296142355
Cited by
194
References
25
FWCI
6.44
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.